vs
Nutex Health, Inc.（NUTX）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Nutex Health, Inc.的1.4倍（$207.3M vs $151.7M），Nutex Health, Inc.净利率更高（7.8% vs -62.0%，领先69.8%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -41.1%），Nutex Health, Inc.自由现金流更多（$69.0M vs $-100.8M），过去两年Nutex Health, Inc.的营收复合增速更高（50.0% vs 38.0%）
Nutex Health是一家总部位于美国得克萨斯州休斯敦的营利性医疗企业，核心业务为运营各类医疗机构，是美国本土医疗领域的专业运营机构，致力于为当地市场提供相关医疗服务与场地运营支持。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
NUTX vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $151.7M | $207.3M |
| 净利润 | $11.8M | $-128.6M |
| 毛利率 | 30.4% | — |
| 营业利润率 | 20.4% | -54.7% |
| 净利率 | 7.8% | -62.0% |
| 营收同比 | -41.1% | 25.9% |
| 净利润同比 | -80.8% | 3.5% |
| 每股收益（稀释后） | $2.34 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $151.7M | $207.3M | ||
| Q3 25 | $267.8M | $159.9M | ||
| Q2 25 | $244.0M | $166.5M | ||
| Q1 25 | $211.8M | $139.3M | ||
| Q4 24 | $257.6M | $164.6M | ||
| Q3 24 | $78.8M | $139.5M | ||
| Q2 24 | $76.1M | $147.0M | ||
| Q1 24 | $67.5M | $108.8M |
| Q4 25 | $11.8M | $-128.6M | ||
| Q3 25 | $55.4M | $-180.4M | ||
| Q2 25 | $-17.7M | $-115.0M | ||
| Q1 25 | $21.2M | $-151.1M | ||
| Q4 24 | $61.6M | $-133.2M | ||
| Q3 24 | $-8.8M | $-133.5M | ||
| Q2 24 | $-364.0K | $-131.6M | ||
| Q1 24 | $-364.0K | $-170.7M |
| Q4 25 | 30.4% | — | ||
| Q3 25 | 57.8% | — | ||
| Q2 25 | 51.2% | — | ||
| Q1 25 | 55.9% | — | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 27.8% | — | ||
| Q2 24 | 29.7% | — | ||
| Q1 24 | 15.1% | — |
| Q4 25 | 20.4% | -54.7% | ||
| Q3 25 | 48.7% | -106.9% | ||
| Q2 25 | 13.8% | -64.8% | ||
| Q1 25 | 38.1% | -102.6% | ||
| Q4 24 | 44.4% | -74.3% | ||
| Q3 24 | 12.3% | -94.6% | ||
| Q2 24 | 7.0% | -79.1% | ||
| Q1 24 | 2.1% | -151.9% |
| Q4 25 | 7.8% | -62.0% | ||
| Q3 25 | 20.7% | -112.8% | ||
| Q2 25 | -7.3% | -69.0% | ||
| Q1 25 | 10.0% | -108.5% | ||
| Q4 24 | 23.9% | -80.9% | ||
| Q3 24 | -11.2% | -95.7% | ||
| Q2 24 | -0.5% | -89.5% | ||
| Q1 24 | -0.5% | -156.8% |
| Q4 25 | $2.34 | $-1.28 | ||
| Q3 25 | $7.76 | $-1.81 | ||
| Q2 25 | $-2.95 | $-1.17 | ||
| Q1 25 | $3.33 | $-1.57 | ||
| Q4 24 | $11.56 | $-1.34 | ||
| Q3 24 | $-1.72 | $-1.40 | ||
| Q2 24 | $-0.07 | $-1.52 | ||
| Q1 24 | $-0.08 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $185.6M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $329.4M | $-80.0M |
| 总资产 | $918.5M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $185.6M | $421.0M | ||
| Q3 25 | $166.0M | $202.5M | ||
| Q2 25 | $96.7M | $176.3M | ||
| Q1 25 | $84.7M | $127.1M | ||
| Q4 24 | $40.6M | $174.0M | ||
| Q3 24 | $46.9M | $150.6M | ||
| Q2 24 | $40.8M | $480.7M | ||
| Q1 24 | $30.0M | $112.3M |
| Q4 25 | $329.4M | $-80.0M | ||
| Q3 25 | $317.2M | $9.2M | ||
| Q2 25 | $235.3M | $151.3M | ||
| Q1 25 | $176.9M | $144.2M | ||
| Q4 24 | $132.4M | $255.0M | ||
| Q3 24 | $60.4M | $346.8M | ||
| Q2 24 | $62.7M | $432.4M | ||
| Q1 24 | $63.0M | $140.3M |
| Q4 25 | $918.5M | $1.5B | ||
| Q3 25 | $964.5M | $1.2B | ||
| Q2 25 | $841.0M | $1.3B | ||
| Q1 25 | $761.9M | $1.3B | ||
| Q4 24 | $655.3M | $1.5B | ||
| Q3 24 | $438.5M | $1.5B | ||
| Q2 24 | $422.4M | $1.6B | ||
| Q1 24 | $404.3M | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $70.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $69.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 45.5% | -48.6% |
| 资本支出强度资本支出/营收 | 0.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 5.95× | — |
| 过去12个月自由现金流最近4个季度 | $245.6M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $70.4M | $-99.8M | ||
| Q3 25 | $99.5M | $-91.4M | ||
| Q2 25 | $27.3M | $-108.3M | ||
| Q1 25 | $51.0M | $-166.5M | ||
| Q4 24 | $54.0K | $-79.3M | ||
| Q3 24 | $6.8M | $-67.0M | ||
| Q2 24 | $13.3M | $-77.0M | ||
| Q1 24 | $3.1M | $-190.7M |
| Q4 25 | $69.0M | $-100.8M | ||
| Q3 25 | $99.2M | $-92.7M | ||
| Q2 25 | $26.5M | $-110.7M | ||
| Q1 25 | $50.9M | $-167.8M | ||
| Q4 24 | $-341.0K | $-79.5M | ||
| Q3 24 | $6.2M | $-68.6M | ||
| Q2 24 | $12.7M | $-79.0M | ||
| Q1 24 | $2.3M | $-193.9M |
| Q4 25 | 45.5% | -48.6% | ||
| Q3 25 | 37.0% | -58.0% | ||
| Q2 25 | 10.9% | -66.5% | ||
| Q1 25 | 24.0% | -120.5% | ||
| Q4 24 | -0.1% | -48.3% | ||
| Q3 24 | 7.8% | -49.2% | ||
| Q2 24 | 16.7% | -53.7% | ||
| Q1 24 | 3.4% | -178.2% |
| Q4 25 | 0.9% | 0.5% | ||
| Q3 25 | 0.1% | 0.8% | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 0.0% | 1.0% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.8% | 1.2% | ||
| Q2 24 | 0.7% | 1.4% | ||
| Q1 24 | 1.1% | 3.0% |
| Q4 25 | 5.95× | — | ||
| Q3 25 | 1.80× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 2.40× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NUTX
| Hospital Division | $143.7M | 95% |
| Population Health Management Division | $8.0M | 5% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
